

David J Schneider

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3713082/publications.pdf>

Version: 2024-02-01

155
papers

7,476
citations

61857

43
h-index

56606

83
g-index

165
all docs

165
docs citations

165
times ranked

7168
citing authors

#	ARTICLE	IF	CITATIONS
1	Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorbâ„¢-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. <i>American Heart Journal</i> , 2022, 245, 19-28.	1.2	4
2	Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation. <i>Clinical Pharmacokinetics</i> , 2022, 61, 465-479.	1.6	14
3	Platelet FcÎ³R1a Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity. , 2022, 2, .		0
4	The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study. <i>Cardiology and Therapy</i> , 2021, 10, 189-199.	1.1	8
5	Endothelial Shear Stress and Platelet FcÎ³R1a Expression in Intracranial Atherosclerotic Disease. <i>Frontiers in Neurology</i> , 2021, 12, 646309.	1.1	1
6	Assessing Pharmacodynamic Effects of Antiplatelet Agents With Different Mechanisms of Action. <i>Journal of the American Heart Association</i> , 2021, 10, e020859.	1.6	1
7	Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic Effects of Aspirin. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 297-301.	0.8	2
8	The Effect of Dapagliflozin on Platelet Function Testing Profiles in Diabetic Patients: The EDGE Pilot Study. <i>Cardiology and Therapy</i> , 2021, 10, 561-568.	1.1	6
9	Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcÎ³R1a. <i>American Journal of Cardiology</i> , 2020, 125, 670-672.	0.7	7
10	The Effect of Low-Dose Ticagrelor on Platelet Function Profiles in Patients With Stable Coronary Artery Disease in Trinidad: The TWIST Pilot Study. <i>Cardiology and Therapy</i> , 2020, 9, 493-503.	1.1	1
11	Prolonged Clotting Time Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2019, 74, 820-821.	1.2	5
12	TRimetazidine as an Agent to affect clopidogrel Response: The TRACER Study. <i>Cardiology and Therapy</i> , 2019, 8, 229-237.	1.1	3
13	BARI 2D: A Reanalysis Focusing on Cardiovascular Events. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2249-2262.	1.4	3
14	Surveillance and Management of Troponin Elevation after Vascular Surgery. <i>Annals of Vascular Surgery</i> , 2019, 60, 156-164.	0.4	4
15	Variation in platelet expression of FcÎ³R1a after myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 88-94.	1.0	6
16	Platelet Function Testing and Clinical Outcomes. <i>JACC Basic To Translational Science</i> , 2019, 4, 776-777.	1.9	0
17	Underutilization of antiplatelet and statin therapy after postoperative myocardial infarction following vascular surgery. <i>Journal of Vascular Surgery</i> , 2018, 67, 279-286.e2.	0.6	7
18	FcÎ³R1a. <i>Journal of the American College of Cardiology</i> , 2018, 72, 237-238.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Antiplatelet therapy for patients undergoing coronary artery bypass surgery. <i>Kardiologia Polska</i> , 2018, 76, 945-952.	0.3	6
20	Use of platelet function testing to guide the timing of coronary artery bypass surgery. <i>Coronary Artery Disease</i> , 2017, 28, 454-456.	0.3	0
21	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
22	Transition strategies from cangrelor to oral platelet P2Y ₁₂ receptor antagonists. <i>Coronary Artery Disease</i> , 2016, 27, 65-69.	0.3	15
23	Novel oral anticoagulants in the management of coronary artery disease. <i>Coronary Artery Disease</i> , 2016, 27, 412-419.	0.3	4
24	Platelet phenotype changes associated with breast cancer and its treatment. <i>Platelets</i> , 2016, 27, 703-711.	1.1	26
25	Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery. <i>Coronary Artery Disease</i> , 2016, 27, 185-190.	0.3	3
26	Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation. <i>Journal of Interventional Cardiology</i> , 2015, 28, 415-419.	0.5	29
27	Bivalirudin versus heparin use for patients undergoing PPCI. <i>Lancet, The</i> , 2015, 385, 2044.	6.3	0
28	Pharmacodynamic effects during the transition between cangrelor and prasugrel. <i>Coronary Artery Disease</i> , 2015, 26, 42-48.	0.3	60
29	Pharmacodynamic Effects During the Transition Between Cangrelor and Ticagrelor. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 435-442.	1.1	68
30	Increased local cytokine production at culprit superficial femoral artery plaques. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 293-299.	1.0	4
31	Depletion of systemic concentrations of coagulation factors in blood from patients with atherosclerotic vascular disease. <i>Coronary Artery Disease</i> , 2013, 24, 468-474.	0.3	7
32	Effect of Exercise Training and Weight Loss on Platelet Reactivity in Overweight Patients With Coronary Artery Disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2013, 33, 371-377.	1.2	19
33	Memorial to Dr Burton E. Sobel. <i>Coronary Artery Disease</i> , 2013, 24, 534.	0.3	0
34	Potential Contribution of Pleiotropic Effects of Direct Anticoagulants to Clinical Benefits. <i>Drug Development Research</i> , 2013, 74, 472-477.	1.4	2
35	PAI-1 and Diabetes: A Journey From the Bench to the Bedside. <i>Diabetes Care</i> , 2012, 35, 1961-1967.	4.3	67
36	New antithrombotic agents for the treatment of coronary artery disease. <i>Coronary Artery Disease</i> , 2012, 23, 367.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment. <i>Coronary Artery Disease</i> , 2012, 23, 208-214.	0.3	3
38	TCT-157 Increased Local Cytokine Production at Culprit Superficial Femoral Artery Plaques. <i>Journal of the American College of Cardiology</i> , 2012, 60, B45-B46.	1.2	0
39	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 9-19.	13.9	1,681
40	Effects on platelet function of a direct acting antagonist of coagulation factor Xa. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 291-296.	1.0	17
41	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 44-55.	1.0	131
42	Change of energy expenditure from physical activity is the most powerful determinant of improved insulin sensitivity in overweight patients with coronary artery disease participating in an intensive lifestyle modification program. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 672-679.	1.5	8
43	Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. <i>Circulation</i> , 2011, 124, 695-703.	1.6	69
44	Mechanisms Potentially Contributing to the Reduction in Mortality Associated With Ticagrelor Therapy. <i>Journal of the American College of Cardiology</i> , 2011, 57, 685-687.	1.2	33
45	Biomarker profiles as descriptors of left ventricular remodeling after acute myocardial infarction. <i>Coronary Artery Disease</i> , 2011, 22, 311-316.	0.3	1
46	Current Issues with Glycoprotein IIb/IIIa Antagonists. <i>Current Drug Targets</i> , 2011, 12, 1813-1820.	1.0	2
47	The Effect of Weight Loss and Exercise Training on Flow-Mediated Dilatation in Coronary Heart Disease. <i>Chest</i> , 2011, 140, 1420-1427.	0.4	50
48	Antiplatelet therapy: glycoprotein IIb/IIIa antagonists. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 672-682.	1.1	60
49	Platelet-white blood cell (WBC) interaction, WBC apoptosis, and procoagulant activity in stored red blood cells. <i>Transfusion</i> , 2011, 51, 1086-1095.	0.8	41
50	Recent developments in the use of antiplatelet agents to prevent cardiovascular events. <i>Future Cardiology</i> , 2011, 7, 403-413.	0.5	6
51	Blood gene expression signatures associate with heart failure outcomes. <i>Physiological Genomics</i> , 2011, 43, 392-397.	1.0	19
52	Depletion of Systemic Concentrations of Coagulation Factors in Blood From Patients with Atherosclerotic Vascular Disease. <i>Blood</i> , 2011, 118, 1231-1231.	0.6	6
53	Frequency and safety of switching antithrombin therapy at a regional PCI center. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 282-288.	1.0	1
54	Factors Contributing to Increased Platelet Reactivity in People With Diabetes. <i>Diabetes Care</i> , 2009, 32, 525-527.	4.3	146

#	ARTICLE	IF	CITATIONS
55	The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease. <i>Circulation</i> , 2009, 120, 2529-2540.	1.6	247
56	High-Calorie-Expenditure Exercise. <i>Circulation</i> , 2009, 119, 2671-2678.	1.6	171
57	A Profibrotic Effect of Plasminogen Activator Inhibitor Type-1 (PAI-1) in the Heart. <i>Experimental Biology and Medicine</i> , 2009, 234, 246-254.	1.1	32
58	Augmentation of Megakaryocyte Expression of Fc γ R1a by Interferon γ . <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1138-1143.	1.1	8
59	Association Between Increased Platelet P-Selectin Expression and Obesity in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 944-949.	4.3	34
60	The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 38-45.	1.0	8
61	Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 6-9.	1.0	4
62	Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation. <i>Coronary Artery Disease</i> , 2009, 20, 175-178.	0.3	6
63	Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: a prospective randomized study. <i>Coronary Artery Disease</i> , 2009, 20, 100-105.	0.3	16
64	Effect of a Computerized Referral at Hospital Discharge on Cardiac Rehabilitation Participation Rates. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2009, 29, 365-369.	1.2	25
65	Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 8-13.	1.0	11
66	Gender-Dependent Differences in Echocardiographic Characteristics of Murine Hearts. <i>Echocardiography</i> , 2008, 25, 739-748.	0.3	11
67	Induction of platelet white blood cell (WBC) aggregate formation by platelets and WBCs in red blood cell units. <i>Transfusion</i> , 2008, 48, 1099-1105.	0.8	10
68	Contributions of young platelets and of previously activated platelets to platelet reactivity in patients with coronary artery disease. <i>Thrombosis Research</i> , 2008, 121, 455-462.	0.8	7
69	Attenuation of apoptosis and the eye of the beholder. <i>Coronary Artery Disease</i> , 2008, 19, 55-58.	0.3	7
70	A Novel Role for Tissue-Type Plasminogen Activator. <i>Circulation</i> , 2008, 118, 1408-1409.	1.6	7
71	The effect of plasminogen activator inhibitor type 1 on apoptosis. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1037-1040.	1.8	55
72	The effect of plasminogen activator inhibitor type 1 on apoptosis. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1037-40.	1.8	31

#	ARTICLE	IF	CITATIONS
73	Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs. <i>Circulation</i> , 2007, 116, 305-315.	1.6	28
74	On rendering continuous glucose monitoring ready for prime time in the cardiac care unit. <i>Coronary Artery Disease</i> , 2007, 18, 405-409.	0.3	4
75	Adenosine Diphosphate-Induced Platelet Aggregation Correlates with Platelet Activation Identified with the Use of Flow Cytometry. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2007, 36, 75-79.	0.5	0
76	Increased platelet expression of FcGammaRIIa and its potential impact on platelet reactivity in patients with end stage renal disease. <i>Thrombosis Journal</i> , 2007, 5, 7.	0.9	5
77	Influence of Preparative Procedures on Assay of Platelet Function and Apparent Effects of Antiplatelet Agents. <i>American Journal of Cardiology</i> , 2007, 100, 722-727.	0.7	10
78	Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants. <i>Histochemistry and Cell Biology</i> , 2007, 128, 135-145.	0.8	28
79	A novel dual staining method for identification of apoptotic cells reveals a modest apoptotic response in infarcted mouse myocardium. <i>Histochemistry and Cell Biology</i> , 2007, 128, 275-283.	0.8	12
80	The Impact of P2Y-Mediated Activation on Release of Angiogenic Proteins by Platelets from Healthy Individuals.. <i>Blood</i> , 2007, 110, 3894-3894.	0.6	0
81	Coronary intervention in patients with diabetes, chronic renal disease, and the elderly: therapeutic implications. <i>Reviews in Cardiovascular Medicine</i> , 2007, 8 Suppl 3, S35-41.	0.5	1
82	wnt3a but not wnt11 supports self-renewal of embryonic stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 789-795.	1.0	110
83	Insulin resistance increases PAI-1 in the heart. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 102-107.	1.0	22
84	Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. <i>Life Sciences</i> , 2006, 79, 1600-1605.	2.0	17
85	Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. <i>Thrombosis Research</i> , 2006, 118, 361-369.	0.8	44
86	Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibatide on thrombin-induced platelet activation. <i>Coronary Artery Disease</i> , 2006, 17, 471-476.	0.3	19
87	Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus. <i>Coronary Artery Disease</i> , 2006, 17, 57-61.	0.3	5
88	Osteoprotegerin is not associated with angiographic coronary calcification. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 177-183.	1.0	6
89	Augmentation of Proliferation of Vascular Smooth Muscle Cells by Plasminogen Activator Inhibitor Type 1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1777-1783.	1.1	75
90	Quantitative Analysis of Atherosclerotic Lesion Composition in Mice. <i>Methods in Molecular Biology</i> , 2006, 319, 137-152.	0.4	8

#	ARTICLE	IF	CITATIONS
91	Platelet protagonist/antagonist: understanding the distinguishing characteristics of anticoagulants. <i>Reviews in Cardiovascular Medicine</i> , 2006, 7 Suppl 3, S3-11.	0.5	0
92	Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. <i>Coronary Artery Disease</i> , 2005, 16, 473-476.	0.3	51
93	The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. <i>Coronary Artery Disease</i> , 2005, 16, 401-405.	0.3	13
94	Variation in the Ability of Glycoprotein IIb-IIIa Antagonists to Exert and Maintain Their Inhibitory Effects on the Binding of Fibrinogen. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 46, 41-45.	0.8	6
95	Relation of Leukocytosis to C-Reactive Protein and Interleukin-6 Among Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2005, 96, 538-542.	0.7	14
96	Systemic Inflammation After Drug-Eluting Stent Placement. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 87-92.	1.0	34
97	Attenuation of Accumulation of Neointimal Lipid by Pioglitazone in Mice Genetically Deficient in Insulin Receptor Substrate-2 and Apolipoprotein E. <i>Journal of Histochemistry and Cytochemistry</i> , 2005, 53, 603-610.	1.3	23
98	Cardiovascular complications in diabetes mellitus. <i>Current Opinion in Pharmacology</i> , 2005, 5, 143-148.	1.7	57
99	Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1559-1563.	0.4	29
100	Attenuation of Neointimal Vascular Smooth Muscle Cellularity in Atheroma by Plasminogen Activator Inhibitor Type 1 (PAI-1). <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 1091-1099.	1.3	44
101	Development of glycoprotein IIb/IIIa antagonists: translation of pharmacodynamic effects into clinical benefit. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 903-913.	0.6	19
102	Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. <i>American Journal of Cardiology</i> , 2004, 93, 6-9.	0.7	36
103	Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. <i>American Journal of Cardiology</i> , 2004, 94, 725-728.	0.7	44
104	Endothelial dysfunction and inflammation after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004, 94, 1420-1423.	0.7	38
105	Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. <i>Journal of Cellular Biochemistry</i> , 2004, 92, 178-188.	1.2	89
106	Platelet function, coagulopathy, and impaired fibrinolysis in diabetes. <i>Cardiology Clinics</i> , 2004, 22, 511-526.	0.9	57
107	Efficiency in clinical research: assessment in vitro of potential anti-thrombotic drug interactions. <i>Coronary Artery Disease</i> , 2004, 15, 177-181.	0.3	5
108	Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. <i>Coronary Artery Disease</i> , 2004, 15, 471-475.	0.3	33

#	ARTICLE	IF	CITATIONS
109	Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory response. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 15, 25-31.	1.0	33
110	Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. <i>American Journal of Cardiology</i> , 2003, 92, 1362-1365.	0.7	115
111	Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. <i>American Journal of Cardiology</i> , 2003, 91, 334-336.	0.7	71
112	Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. <i>American Journal of Cardiology</i> , 2003, 91, 876-878.	0.7	37
113	Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. <i>American Journal of Cardiology</i> , 2003, 91, 1346-1349.	0.7	28
114	Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. <i>American Journal of Cardiology</i> , 2003, 92, 924-929.	0.7	28
115	Intramural Plasminogen Activator Inhibitor Type-1 and Coronary Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1979-1989.	1.1	113
116	Title is missing!. <i>Coronary Artery Disease</i> , 2003, 14, 353-355.	0.3	0
117	Effect of Combination Glipizide/GITS/Metformin on Fibrinolytic and Metabolic Parameters in Poorly Controlled Type 2 Diabetic Subjects. <i>Diabetes Care</i> , 2002, 25, 2123-2128.	4.3	53
118	The Independence of Signaling Pathways Mediating Increased Expression of Plasminogen Activator Inhibitor Type1 in HepG2 Cells Exposed to Free Fatty Acids or Triglycerides. <i>International Journal of Experimental Diabetes Research</i> , 2002, 3, 109-118.	1.0	12
119	Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. <i>American Journal of Cardiology</i> , 2002, 89, 647-650.	0.7	92
120	Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. <i>American Journal of Cardiology</i> , 2002, 90, 1421-1423.	0.7	68
121	Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: A potential contributor to cardiovascular risk. <i>American Journal of Kidney Diseases</i> , 2002, 40, 315-322.	2.1	66
122	Delineation of the evolution of compositional changes in atheroma. <i>Histochemistry and Cell Biology</i> , 2002, 118, 59-68.	0.8	17
123	Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 13, 161-165.	1.0	42
124	Time and Dose Dependent Augmentation of Inhibitory Effects of Abciximab by Aspirin. <i>Thrombosis and Haemostasis</i> , 2001, 85, 309-313.	1.8	24
125	Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab. <i>Coronary Artery Disease</i> , 2001, 12, 245-253.	0.3	17
126	Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 12, 171-176.	1.0	17

#	ARTICLE	IF	CITATIONS
127	Platelet Reactivity Characterized Prospectively. <i>Circulation</i> , 2001, 104, 181-186.	1.6	147
128	Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. <i>American Journal of Cardiology</i> , 2000, 85, 491-493.	0.7	91
129	Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease. <i>American Journal of Cardiology</i> , 2000, 85, 784-786.	0.7	17
130	Abciximab-Associated Pseudothrombocytopenia. <i>Circulation</i> , 2000, 101, 938-939.	1.6	17
131	Identification and Localization of a Fatty Acid Response Region in the Human Plasminogen Activator Inhibitor-1 Gene. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2696-2701.	1.1	46
132	Novel, Bedside, Tissue Factor-Dependent Clotting Assay Permits Improved Assessment of Combination Antithrombotic and Antiplatelet Therapy. <i>Circulation</i> , 2000, 102, 2051-2057.	1.6	29
133	The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine. <i>American Journal of Cardiology</i> , 1999, 83, 770-774.	0.7	15
134	Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. <i>American Journal of Cardiology</i> , 1999, 84, 203-207.	0.7	50
135	Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein. <i>Journal of the American College of Cardiology</i> , 1999, 33, 261-266.	1.2	66
136	Differences between Activation Thresholds for Platelet P-Selectin and Glycoprotein IIb-IIIa Expression and Their Clinical Implications. <i>Thrombosis Research</i> , 1999, 95, 75-82.	0.8	50
137	The retardation of vasculopathy induced by attenuation of insulin resistance in the corpulent JCR:LA-cp rat is reflected by decreased vascular smooth muscle proliferation in vivo. <i>Atherosclerosis</i> , 1999, 143, 245-251.	0.4	39
138	Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions. , 1998, 44, 257-264.		9
139	Increased Plasminogen Activator Inhibitor Type 1 in Coronary Artery Atherectomy Specimens From Type 2 Diabetic Compared With Nondiabetic Patients. <i>Circulation</i> , 1998, 97, 2213-2221.	1.6	270
140	Acute Coronary Syndromes: 1. The Platelet's Role. <i>Hospital Practice (1995)</i> , 1998, 33, 171-185.	0.5	5
141	Acute Coronary Syndromes: 2. Antiplatelet Agents. <i>Hospital Practice (1995)</i> , 1998, 33, 107-130.	0.5	0
142	Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2108-2116.	1.8	389
143	Immunoelectron Microscopic Localization of Plasminogen Activator Inhibitor Type 1 (PAI-1) in Smooth Muscle Cells from Morphologically Normal and Atherosclerotic Human Arteries. <i>Ultrastructural Pathology</i> , 1997, 21, 527-536.	0.4	11
144	Increased proliferation of explanted vascular smooth muscle cells: a marker presaging atherogenesis. <i>Atherosclerosis</i> , 1997, 131, 187-194.	0.4	46

#	ARTICLE	IF	CITATIONS
145	Altered Expression of Troponin T Isoforms in Mild Left Ventricular Hypertrophy in the Rabbit. <i>Journal of Molecular and Cellular Cardiology</i> , 1997, 29, 2345-2354.	0.9	23
146	Changes in Arterial Expression of Fibrinolytic System Proteins in Atherogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3294-3301.	1.1	61
147	Determinants of coronary vascular disease in patients with type ii diabetes mellitus and their therapeutic implications. <i>Clinical Cardiology</i> , 1997, 20, 433-440.	0.7	27
148	Dependence of Augmentation of Arterial Endothelial Cell Expression of Plasminogen Activator Inhibitor Type 1 by Insulin on Soluble Factors Released From Vascular Smooth Muscle Cells. <i>Circulation</i> , 1997, 96, 2868-2876.	1.6	48
149	Differential Effects of Anticoagulants on the Activation of Platelets Ex Vivo. <i>Circulation</i> , 1997, 96, 2877-2883.	1.6	92
150	Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. <i>Coronary Artery Disease</i> , 1996, 7, 813-818.	0.3	69
151	Attenuated Fibrinolysis and Accelerated Atherogenesis in Type II Diabetic Patients. <i>Diabetes</i> , 1993, 42, 1-7.	0.3	164
152	Constitutive biosynthesis of plasminogen activator inhibitor type-1 (PAI-1) by cultured human aortic endothelial cells independent of insulin. <i>Coronary Artery Disease</i> , 1993, 4, 713-720.	0.3	16
153	Stimulation by Proinsulin of Expression of Plasminogen Activator Inhibitor Type-I in Endothelial Cells. <i>Diabetes</i> , 1992, 41, 890-895.	0.3	128
154	Effect of diabetes on the coagulation and fibrinolytic systems and its implications for atherogenesis. <i>Coronary Artery Disease</i> , 1992, 3, 26-32.	0.3	22
155	Cardiac ramifications of cocaine abuse. <i>Coronary Artery Disease</i> , 1991, 2, 267-274.	0.3	9